Ensign Peak Advisors
CHRS icon

Ensign Peak Advisors’s Coherus Oncology CHRS Stock Holding History

Ensign Peak Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,490
Closed -$207K – 1870
2022
Q3 		$207K Buy
21,490
+1,390
+7% +$14.1K ﹤0.01% 1861
2022
Q2 		$146K Hold
20,100
– – ﹤0.01% 1887
2022
Q1 		$259K Hold
20,100
– – ﹤0.01% 1802
2021
Q4 		$321K Hold
20,100
– – ﹤0.01% 1793
2021
Q3 		$323K Buy
20,100
+6,500
+48% +$95.3K ﹤0.01% 1700
2021
Q2 		$188K Buy
13,600
+2,000
+17% +$28.3K ﹤0.01% 1729
2021
Q1 		$169K Hold
11,600
– – ﹤0.01% 1744
2020
Q4 		$202K Buy
+11,600
New +$207K ﹤0.01% 1723
2020
Q2 		– Sell
-3,457
Closed -$56K – 1677
2020
Q1 		$56K Sell
3,457
-14,277
-81% -$264K ﹤0.01% 1601
2019
Q4 		$319K Buy
+17,734
New +$327K ﹤0.01% 1584

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ensign Peak Advisors's CHRS Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 21,490 shares — an estimated $207K sold.

Ensign Peak Advisors first reported a position in CHRS in Q4 2019 and held it in 10 quarters. The position peaked at $323K in Q3 2021. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 21,490 Coherus Oncology shares in Q4 2022, an estimated $207K.
  • Ensign Peak Advisors first reported a position in Coherus Oncology in Q4 2019 and held it in 10 quarters.
  • Ensign Peak Advisors's Coherus Oncology position peaked at $323K in Q3 2021.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.